

Remarks

Claims 1-30 and 34-38 were pending.

Claims 1-3, 5, 10 and 22-38 are cancelled.

Claims 4, 6-9, 11, 12, 14, 18 and 19 are amended.

Claims 13, 15 and 16 are as previously presented.

Claims 17, 20 and 21 are original.

The application now contains claims 4, 6-9 and 11-21.

Claim 4 is amended to directly incorporate the limitations of now cancelled claim 1 from which it depended.

Claim 12 is amended to directly incorporate the limitations of now cancelled claim 1 from which it depended.

Claims 6-8 and 11 are amended to be dependent on claim 4; claim 9 is amended to be dependent on claim 8; claim 14 is amended to be dependent on claim 12.

Claim 6 is further amended to delete the term "(non-polar)" from line 4 and to delete the term "(acrylate monomers)" from line 5.

Claim 7 is further amended incorporate the limitations that " X^- is the anion of an organic acid" of now cancelled claim 5 from which it depended.

Claim 14 is further amended to delete the material already recited in parent claim 12 and to reword the additional material from step b) of original claim 14. For clarity, the reworded material is placed immediately following the phrase "gravure printing ink compositions" in line 1.

Claim 18 is amended to delete the term "(acrylate monomers)" from line 5.

Claim 19 is amended to correct the spelling of the word "from" in line 4.

No new matter is added.

Objections / Rejections

Claims 4, 7, 12-21, 29 and 30 were objected to as being dependent on a rejected base claim but would be found allowable if rewritten as independent claims incorporating all the limitations of the base claim and any intervening claims. Claims 4 and 12 have been rewritten as independent claims incorporating all of the limitations of claim 1. Claim 7 is now dependent on claim 4 and claim 14 is now dependent on claim 12. Claims 29 and 30 are cancelled without prejudice. In light of the amendments above, claims 7 and 13-21 all depend ultimately from either claim 4 or claim 12. Claims 18 and 19 were also amended to include the suggestions made by the Examiner in paragraph 3 on page 2 of the present Action.

In light of the above amendments, Applicants respectfully submit that the above objections are overcome and kindly ask the Examiner to withdraw them and find the claims 4, 7, 12-21 allowable.

Claims 1-3, 5, 6, 8-11, 22-28 and 34-38 are rejected under 102(b) as being anticipated by De Feo et. al., US 4,306,875. Claims 1-3, 5, 10, 22-28 and 34-38 are cancelled. Claims 6, 8 and 11 amended to be dependent on claim 4; claim 9 is amended to be dependent on claim 8. In light of the amendments, claims 6, 8, 9 and 11 all depend ultimately from claim 4. Claim 6 is also amended to include the suggestions made by the Examiner in paragraph 3 on page 2 of the present Action.


Applicants respectfully suggest that in light of the amendments the rejections of claims 6 and 8-11 are addressed and overcome and kindly ask that the Examiner find them allowable.

As there are no other objections or rejections, Applicants kindly ask that claims 4, 6-9, and 11-21 be found allowable. In the event that minor amendments will further prosecution, Applicants request that the examiner contact the undersigned representative.

Ciba Specialty Chemicals Corporation
Patent Department
540 White Plains Road
P.O. Box 2005
Tarrytown, NY 10591-9005
Tel. (914) 785-2973
Fax (914) 785-7102

JAN 11 2007

Respectfully submitted,


Joseph C. Suhadolnik
Agent for Applicants
Reg. No. 56,880
filed under 37 CFR 1.34(a)